Please assess the completion status of the following clinical trial:

Trial Title: Anastrozole in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous documentation of mean pulmonary artery pressure \> 25 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) \< 16 mm Hg and PVR \> 3 WU at any time before study entry.~* Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection.~* Most recent pulmonary function tests with FEV1/FVC \>50% AND either a) total lung capacity \> 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest~* Ability to perform six minute walk testing without limitations in musculoskeletal function or coordination.~* If female, post-menopausal state, defined as:~* \> 50 years old AND~* a) have not menstruated during the preceding 12 months OR~* b) have follicle-stimulating hormone (FSH) levels (\> 40 IU/L) OR~* \< 50 years and FSH (\> 40 IU/L) OR~* having had a bilateral oophorectomy~* Informed consent~Exclusion Criteria:~* Treatment with estrogen or anti-hormone therapy (tamoxifen, fulvestrant, etc.)~* WHO Class IV functional status~* History of breast cancer~* Clinically significant untreated sleep apnea~* Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction \< 45% on echocardiography~* Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors) within three months of enrollment; the dose must be stable for at least 3 months prior to Baseline Visit~* Hormone therapy~* Hospitalized or acutely ill~* Renal failure (creatinine \> 2.0)~* Child-Pugh Class C cirrhosis~* Current or recent (\< 6 months) chronic heavy alcohol consumption~* Current use of another investigational drug (non-FDA approved) for PAH~* Enrollment in a clinical trial within one month of screening~* Age \< 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anastrozole (Type: EXPERIMENTAL): 1 mg tablet by mouth once daily for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet by mouth once daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).